Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xanthomicrol is a **plant-derived, trimethoxylated hydroxyflavone** with reported antineoplastic, antiangiogenic, anti-inflammatory, and antimicrobial activity. Mechanistic studies indicate that xanthomicrol induces cytotoxic and antiproliferative effects in malignant cell lines, selectively reducing cancer cell viability with minimal toxicity to normal cells. Its anticancer activities are due to modulation of lipid metabolism, induction of apoptosis, cell cycle arrest at G2/M phase, and inhibition of de novo lipogenesis. In vivo, xanthomicrol has been shown to inhibit tumor growth and angiogenesis, associated with downregulation of the PI3K/Akt pathway and suppression of HIF-1α and VEGF expression. Molecular modeling studies also suggest xanthomicrol may inhibit DNA methyltransferase 1 (DNMT1), similar to decitabine, suggesting potential epigenetic effects[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xanthomicrol.